Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo
about
A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's diseaseTransthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease?Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectinβ-hairpin-mediated formation of structurally distinct multimers of neurotoxic prion peptidesIntracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study.Immunotherapy as treatment for Alzheimer’s diseaseVitamin A and Alzheimer's diseaseNew Class of Inhibitors of Amyloid-beta Fibril Formation. IMPLICATIONS FOR THE MECHANISM OF PATHOGENESIS IN ALZHEIMER'S DISEASECellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomersNeurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratioProgressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteinsInteractions between fatty acids and alpha-synucleinExcitatory amino acid transporter 2 associates with phosphorylated tau and is localized in neurofibrillary tangles of tauopathic brainsRole of presenilin 1 in structural plasticity of cortical dendritic spines in vivoPresenilin and nicastrin regulate each other and determine amyloid beta-peptide production via complex formationDissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's diseaseNaturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanismThe Alzheimer's amyloid β-peptide (Aβ) binds a specific DNA Aβ-interacting domain (AβID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: characterizing a new regulatory motifInhibition of calpain prevents NMDA-induced cell death and beta-amyloid-induced synaptic dysfunction in hippocampal slice culturesInhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model.Functional activity of the novel Alzheimer's amyloid β-peptide interacting domain (AβID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesisImmunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse modelUpregulation of the E3 ligase NEDD4-1 by oxidative stress degrades IGF-1 receptor protein in neurodegenerationCholinergic-associated loss of hnRNP-A/B in Alzheimer's disease impairs cortical splicing and cognitive function in miceSynthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's diseaseMyD88 deficiency ameliorates β-amyloidosis in an animal model of Alzheimer's diseaseAbeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networksStructural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrilsProtein phosphatases and Alzheimer's diseaseReversing EphB2 depletion rescues cognitive functions in Alzheimer modelMolecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments.Metals and amyloid-beta in Alzheimer's diseaseAmyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memorySoluble oligomers of the amyloid beta-protein impair synaptic plasticity and behaviorHuman serum albumin inhibits Abeta fibrillization through a "monomer-competitor" mechanismLipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in miceProtein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseasesLipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's diseaseReelin signaling antagonizes beta-amyloid at the synapse
P2860
Q21146622-21C82B2C-EEFB-462C-B5B3-C979DECD70E8Q21202832-7C50840B-341B-48B3-A36F-18D3F67D1DF9Q21202837-02589445-CA9F-426B-9814-4BA07D3F811FQ21558493-47E4C152-E4C6-4DBD-8A06-4AEA4A1BE2FDQ22001054-62495BE6-2A02-4AE0-B41D-2A4ACD44B7EAQ22241491-B0A59F10-5480-47D0-A87F-5463FCA42AB9Q22242414-764E70F8-6518-4D02-BB83-CA0D387E6948Q22248067-AE158D33-B7A3-426C-ACA0-1634D2B91F18Q22251089-4C36BAA0-F8B6-4265-BA82-5AD502D2A7BBQ24298670-A8F33F5A-229D-4473-B009-F25CD50DDC3EQ24329069-BC2E9531-B00E-4FD0-8F56-BF2E16492982Q24336967-978603E5-366D-4C88-8396-D9817F60BD83Q24338463-9151F9A6-0035-486A-9F72-4D1DFDC0C8A3Q24338802-F457F666-9CEA-4C1F-973B-3818D0DEB732Q24530721-04B9243B-5B6C-4290-935F-80A890695CFBQ24564815-3EFA72A8-E6BE-41DE-8196-BEBBF0648C35Q24595310-C5C2625A-39BB-43E1-B2C1-284A9855555CQ24600203-2D097C60-C036-45E6-B1BC-6D5D188A50ABQ24603101-68B06808-699E-4D16-A08F-BD052590ED79Q24603560-EEBD4428-84C0-410A-939C-6179E019E756Q24606614-E55D0BBA-BE5C-4740-87DF-687DC7DE2CBAQ24608911-F0E1F7F2-5941-40AE-A3AE-A982E7820DCBQ24613053-3C714112-FE1C-43EC-B0FC-3965696D4935Q24615739-3EAE9DD3-A6BD-4DC4-BC13-427138DE01A1Q24615907-5AB50AD5-90BB-432B-BC4E-1BCE0A214E83Q24616286-14089E23-C7FD-4DE7-8104-C2CF26F3844AQ24620404-BD743837-7AA2-4585-9CAC-CFF3FB78E89DQ24622558-839CB1A3-0F2A-4622-8AF7-3F8EFE79A0DEQ24631702-AED0B8E6-CC69-4573-AACE-31CEDEDBD223Q24632495-2CF0D5FB-9FAC-46F5-B907-A38C7F4DEEB6Q24632892-20432573-86AA-4657-84BF-3A47E5371639Q24633947-CD76117B-DE6D-4F45-9B01-EF99445AA608Q24643555-CA41A976-FC5E-446B-A0B3-D6F0D454A104Q24645499-61747807-D9A6-4092-B192-B56165DF0A31Q24645994-1D6CE64F-C7EB-4C84-9801-E3272F262481Q24646788-5BED89CC-D284-4358-A80D-BFEEA2C519D8Q24649564-3F847081-61CA-4592-9A24-3DD0D609BF26Q24650014-FBE08CBE-6609-4621-B310-D34925632D63Q24650450-A8DE6195-26FD-4EFE-80D2-CB12CAC54EFEQ24651028-DDD3242E-E289-41F0-B405-76D2331AD054
P2860
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Naturally secreted oligomers o ...... long-term potentiation in vivo
@ast
Naturally secreted oligomers o ...... long-term potentiation in vivo
@en
Naturally secreted oligomers o ...... long-term potentiation in vivo
@nl
type
label
Naturally secreted oligomers o ...... long-term potentiation in vivo
@ast
Naturally secreted oligomers o ...... long-term potentiation in vivo
@en
Naturally secreted oligomers o ...... long-term potentiation in vivo
@nl
prefLabel
Naturally secreted oligomers o ...... long-term potentiation in vivo
@ast
Naturally secreted oligomers o ...... long-term potentiation in vivo
@en
Naturally secreted oligomers o ...... long-term potentiation in vivo
@nl
P2093
P3181
P356
P1433
P1476
Naturally secreted oligomers o ...... long-term potentiation in vivo
@en
P2093
Dennis J Selkoe
Dominic M Walsh
Igor Klyubin
Julia V Fadeeva
Michael S Wolfe
Roger Anwyl
William K Cullen
P2888
P3181
P356
10.1038/416535A
P407
P577
2002-04-04T00:00:00Z
P5875
P6179
1026999063